These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12937015)

  • 1. In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2003 Sep; 47(9):3008-11. PubMed ID: 12937015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
    Goldstein EJ; Conrads G; Citron DM; Merriam CV; Warren Y; Tyrrell K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2363-7. PubMed ID: 11451698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
    Goldstein EJ; Conrads G; Citron DM; Merriam CV; Warren Y; Tyrrell K
    Diagn Microbiol Infect Dis; 2002 Feb; 42(2):113-8. PubMed ID: 11858906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activities of amoxicillin-clavulanate against aerobic and anaerobic bacteria isolated from antral puncture specimens from patients with sinusitis.
    Goldstein EJ; Citron DM; Merriam CV
    Antimicrob Agents Chemother; 1999 Mar; 43(3):705-7. PubMed ID: 10049296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis.
    Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrel KL; Fernandez H
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1963-7. PubMed ID: 12760875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes.
    Biedenbach DJ; Jones RN
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1636-42. PubMed ID: 7492122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
    King A; Bethune L; Phillips I
    J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.
    Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1552-7. PubMed ID: 9210683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates.
    Goldstein EJ; Nesbit CA; Citron DM
    Antimicrob Agents Chemother; 1995 May; 39(5):1097-100. PubMed ID: 7625795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Gunderson SM; Hayes RA; Quinn JP; Danziger LH
    Antimicrob Agents Chemother; 2004 Jan; 48(1):203-8. PubMed ID: 14693540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
    Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R
    J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteriological findings and antimicrobial resistance in odontogenic and non-odontogenic chronic maxillary sinusitis.
    Puglisi S; Privitera S; Maiolino L; Serra A; Garotta M; Blandino G; Speciale A
    J Med Microbiol; 2011 Sep; 60(Pt 9):1353-1359. PubMed ID: 21498651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiology of intracranial abscesses and their associated sinusitis.
    Brook I
    Arch Otolaryngol Head Neck Surg; 2005 Nov; 131(11):1017-9. PubMed ID: 16301376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of lomefloxacin, a new difluoroquinolone.
    Clarke AM; Zemcov SJ
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):164-8. PubMed ID: 2498101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
    Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.
    Stein GE; Schooley S; Tyrrell KL; Citron DM; Goldstein EJ
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1308-12. PubMed ID: 12654663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez H
    Antimicrob Agents Chemother; 2002 Mar; 46(3):866-70. PubMed ID: 11850275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
    Citron DM; Appleman MD
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2312-6. PubMed ID: 9333074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
    Tanaka M; Hoshino K; Ishida H; Sato K; Hayakawa I; Osada Y
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.